Welcome to our dedicated page for MAIA Biotechnology SEC filings (Ticker: MAIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MAIA Biotechnology, Inc. filings document the regulatory record for a clinical-stage oncology company developing ateganosine for non-small cell lung cancer. Form 8-K reports cover THIO-101 clinical updates, oncology conference materials, shareholder communications on the development pipeline, FDA Fast Track disclosure, and forward-looking risk language tied to investigational drug development.
The company’s filings also document capital structure and governance matters, including an underwritten common stock offering conducted under an effective Form S-3 shelf registration, the related underwriting agreement and use-of-proceeds disclosure, executive compensation actions, and annual meeting proxy matters such as director elections and auditor ratification.
MAIA Biotechnology files its annual report describing rapid progress for its lead cancer drug, ateganosine (THIO), and a growing telomere-targeting pipeline. The company is running the pivotal Phase 2 THIO-101 trial in third-line non-small cell lung cancer (NSCLC) and has initiated the Phase 3 THIO-104 trial comparing ateganosine plus a checkpoint inhibitor to chemotherapy in up to 300 patients.
Ateganosine has shown encouraging interim results in NSCLC, including median overall survival around 17.8 months in heavily pretreated third-line patients, strong disease control and overall response rates, and generally manageable safety. MAIA has secured multiple FDA designations, including Orphan Drug, Fast Track and rare pediatric disease status, and expanded global collaborations with Regeneron, BeiGene/BeOne and Roche, while building a second-generation telomere-targeting prodrug platform and an extensive patent estate.
MAIA Biotechnology, Inc. entered into an underwriting agreement for an underwritten public offering of 20,000,000 shares of common stock at a public offering price of $1.50 per share, for gross proceeds of approximately $30 million before fees and expenses. The underwriter has a 30-day option to buy up to an additional 3,000,000 shares to cover over-allotments. The deal is issued off MAIA’s effective Form S-3 shelf registration and closed on March 4, 2026. Company officers and directors agreed to a 60-day lock-up on certain sales, and MAIA plans to use net proceeds to fund clinical trials, working capital, and general corporate purposes.
MAIA Biotechnology, Inc. is offering 20,000,000 shares of common stock at a public offering price of $1.50 per share.
The offering includes a 30-day option for the underwriters to purchase up to 3,000,000 additional shares. The underwriters expect to deliver the shares on or about March 4, 2026. Estimated net proceeds to the company are approximately $28.0 million, or approximately $32.3 million if the over-allotment option is fully exercised. The prospectus supplement bases post-offering outstanding shares on 38,659,579 shares as of March 2, 2026.
MAIA Biotechnology, Inc. is offering shares of its common stock and pre-funded warrants pursuant to a shelf prospectus supplement dated March 2, 2026. The pre-funded warrants are offered to purchasers who would otherwise exceed 4.99% (or, at the election of the purchaser, 9.99%) beneficial ownership post-offering. Each pre-funded warrant is exercisable for one share at an exercise price of $0.0001 and will be immediately exercisable. The prospectus references the company’s NYSE American listing under the symbol MAIA and reports 38,659,579 shares outstanding as of March 2, 2026 in the offering context. The document discloses underwriting arrangements, a 30-day 15% overallotment option, intended use of proceeds for clinical trials and working capital, and risk factors regarding dilution, liquidity for pre-funded warrants, and the company’s financing needs.
MAIA Biotechnology filed an 8-K to share a 2026 shareholder letter and press release highlighting progress for its lead cancer drug candidate, ateganosine, in non-small cell lung cancer (NSCLC). The company is running an ongoing Phase 3 full-approval clinical trial, which it describes as having a high probability of technical success for interim and full analyses.
Ateganosine is presented as a first-in-class, telomere-targeting immunotherapy being developed initially as a third-line treatment for NSCLC patients who have failed prior checkpoint inhibitor and chemotherapy regimens. MAIA emphasizes the lack of an established standard of care in this setting, estimating a U.S. population of about 50,000 such patients annually and positioning ateganosine as creating a differentiated revenue opportunity.
The company notes FDA Fast Track designation for ateganosine as third-line NSCLC therapy and references a potential commercial opportunity within a cited $50 billion global immunotherapy market. Management’s letter underscores optimism about the program’s momentum, the broader pipeline, and the long-term potential for ateganosine across multiple cancer indications, while including detailed forward-looking statement cautions.
MAIA Biotechnology, Inc. filed a current report to note that it issued a press release titled “MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines 2026 Clinical Milestones and Growth Momentum.” The release, attached as an exhibit, focuses on progress in the company’s Ateganosine cancer treatment program and its planned clinical milestones for 2026.
The report emphasizes that these updates are forward-looking statements and may differ from actual results. MAIA highlights key uncertainties, including the timing, cost and results of preclinical and clinical studies, the ability to advance product candidates through trials and regulatory review, manufacturing and commercialization efforts, market acceptance, market size and growth potential, and the ability to obtain and maintain intellectual property protection.
MAIA Biotechnology, Inc. filed a current report describing new investor presentation materials that its management plans to use from time to time, including at the Biotech Showcase conference in San Francisco, California on January 13, 2026. The presentation materials are included as Exhibit 99.1 and were also posted on the company’s website on January 13, 2026.
The company notes that the presentation materials contain forward-looking statements, emphasizing that readers and investors should be cautious in placing reliance on these statements. The filing is made as a Regulation FD disclosure and an “Other Events” update, with no separate financial results or major transactions described.
MAIA Biotechnology director Stan Smith reported indirect ownership changes in the company’s common stock. On September 19, 2022, The Stan V. Smith Trust Dated 1993, associated with him, purchased 2,700 shares of MAIA common stock at $3.6884 per share, bringing that trust’s reported indirect holdings to 1,424,178 shares.
On May 1, 2024, 20,000 shares previously held in the Stan V Smith CUST Gage Quentin Smith IL UNIF TRNS MIN Act account were transferred at $0 to The Stan V. Smith Trust Dated 1993, increasing that trust’s reported indirect holdings to 1,444,178 shares. Three additional IL Uniform Transfers to Minors Act accounts for family members each hold 4,580 shares, where Smith reports indirect beneficial ownership but disclaims it except to the extent of his pecuniary interest.
MAIA Biotechnology, Inc. reported that a company director received a new stock option grant. On 12/31/2025, the director was granted options to purchase 24,060 shares of MAIA Biotechnology common stock at an exercise price of $1.53 per share under the company’s 2021 Equity Incentive Plan. The options vest 100% on the grant date and are exercisable beginning on that date, with an expiration date of 12/31/2035. Following this grant, the director holds 24,060 derivative securities directly.
MAIA Biotechnology director option grant reported
MAIA Biotechnology, Inc. disclosed that director Stan V. Smith was granted stock options on 12/31/2025 under the company’s 2021 Equity Incentive Plan. The options cover 29,216 shares of common stock at an exercise price of $1.53 per share and vest 100% on the grant date, meaning they are exercisable beginning 12/31/2025.
The options have an expiration date of 12/31/2035. Following this grant, 29,216 derivative securities are shown as beneficially owned indirectly through The Stan V. Smith Trust Dated 1993.